Clinical Trials

Numerous clinical trials spanning Phase I through Phase IV evaluated rimonabant across metabolic and cardiovascular indications—including obesity, type 2 diabetes mellitus, prediabetic states, and atherosclerosis—alongside cannabis dependence and acute pain management. Sponsored by pharmaceutical companies such as Sanofi, public organizations like the National Institute on Drug Abuse, and university medical centers, these studies demonstrated variable recruitment outcomes. Although several clinical trials successfully reached completion, multiple clinical trials were prematurely terminated or withdrawn.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05622994 UNKNOWN
Spinal Cord Injuries
Hospital Nacional de Parapléjicos de Toledo
 2022-11 PHASE2
NCT05398913 COMPLETED
Spinal Cord Injuries
Hospital Nacional de Parapléjicos de Toledo
 2021-05-12 PHASE1; PHASE2
NCT00656487 COMPLETED
Cannabis Dependence; Cannabis Withdrawal
The Scripps Research Institute
 2008-04-30 PHASE2
NCT01041170 COMPLETED
Cannabis; Dependence
National Institute on Drug Abuse (NIDA)
 2006-04-16 PHASE1
NCT00734123 UNKNOWN
Atherosclerosis; Cardiovascular Diseases
Hospital Arnau de Vilanova
 2008-04 PHASE4
NCT00228176 TERMINATED
Carotid Artery Plaque; Arteriosclerosis; Obesity; Metabolic Syndrome X
Sanofi
 2005-08 PHASE3
NCT00263042 TERMINATED
Cardiovascular Disease
Sanofi
 2005-12 PHASE3
NCT00584389 TERMINATED
Obesity
University of Surrey
 2007-07 PHASE4
NCT00325650 TERMINATED
Prediabetic State
Sanofi
 2006-05 PHASE3
NCT00547118 TERMINATED
Schizophrenia; Schizoaffective Disorder; Obesity; Hypertension; Smoking
University of Maryland, Baltimore
 2007-11 PHASE2
NCT00405808 TERMINATED
Obesity
Sanofi
 2006-12 PHASE3
NCT00577148 TERMINATED
Fatty Liver
Sanofi
 2008-02 PHASE3
NCT00478595 TERMINATED
Obesity; Diabetes Mellitus Type 2
Sanofi
 2007-04 PHASE3
NCT00546325 COMPLETED
Diabetes Mellitus, Type 2
Sanofi
 2007-10 PHASE3
NCT00576667 TERMINATED
Fatty Liver
Sanofi
 2008-01 PHASE3
NCT00690456 TERMINATED
Diabetes Mellitus, Type 2
Sanofi
 2008-05 PHASE3
NCT00478972 TERMINATED
Obesity; Diabetes Mellitus Type 2
Sanofi
 2007-04 PHASE3
NCT00603109 TERMINATED
Prader-willi Syndrome
Weill Medical College of Cornell University
 2007-08 PHASE3
NCT00412698 TERMINATED
Obesity; Dyslipidemias
Sanofi
 2006-12 PHASE3
NCT00458081 TERMINATED
Obesity; Microalbuminuria; Diabetes Mellitus, Type 2; Dyslipidemia
Sanofi
 2007-03 PHASE3
NCT00408148 TERMINATED
Obesity
Sanofi
 2006-10 PHASE3
NCT00449605 TERMINATED
Diabetes Mellitus, Type 2
Sanofi
 2007-03 PHASE3
NCT00754689 WITHDRAWN
Diabetes Mellitus, Type 2
Sanofi
 2008-09 PHASE3
NCT00678483 TERMINATED
Obesity; Weight Loss
Sanofi
 2008-04 PHASE3
NCT00434096 TERMINATED
Obesity
Sanofi
 2007-02 PHASE3
NCT00750347 COMPLETED
Pain
University Hospital, Clermont-Ferrand
 2008-09 PHASE1
NCT00750347 Completed
Pain
University Hospital Clermont-Ferrand
 2008-09 Phase 1
NCT00299325 COMPLETED
Metabolic Syndrome
Sanofi
 2006-02 PHASE3
NCT00525681 COMPLETED
Renal Transplantation
University of Oslo School of Pharmacy
 2007-09 PHASE4
NCT00656487 Completed
Cannabis Dependence|Cannabis Withdrawal
The Scripps Research Institute|National Institute on Drug Abuse (NIDA)
 2008-04-30 Phase 2
NCT00636766 COMPLETED
Carotid Atherosclerosis; Stroke; Type 2 Diabetes; Metabolic Syndrome
Aristotle University Of Thessaloniki
 2005-09
NCT00124332 COMPLETED
Coronary Atherosclerosis
Sanofi
 2005-01 PHASE3
NCT00546325 Completed
Diabetes Mellitus Type 2
Sanofi
 2007-10 Phase 3
NCT00525681 Completed
Renal Transplantation
University of Oslo School of Pharmacy
 2007-09 Phase 4
NCT00288236 COMPLETED
Type 2 Diabetes Mellitus
Sanofi
 2006-01 PHASE3
NCT00584389 Terminated
Obesity
University of Surrey|European Foundation for the Study of Diabetes|Royal Surrey County Hospital NHS Foundation Trust
 2007-07 Phase 4
NCT00325546 COMPLETED
Obesity
Sanofi
 2006-04 PHASE3
NCT00075205 COMPLETED
Healthy; Alcohol Drinking
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
 2003-12-31 PHASE2
NCT00239967 COMPLETED
Dyslipidemia; Obesity
Sanofi
 2005-05 PHASE3
NCT00257257 COMPLETED
Type 2 Diabetes Mellitus
Sanofi
 2005-03 PHASE3
NCT00459004 COMPLETED
Obesity
Sanofi
 2004-10 PHASE2
NCT01041170 Completed
Cannabis|Dependence
National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)
 2006-04-16 Phase 1
NCT00459173 COMPLETED
Maintenance of Smoking Cessation
Sanofi
 2002-11 PHASE3
NCT00481975 COMPLETED
Obesity; Eating Disorders
Sanofi
 2004-08 PHASE3
NCT00458718 COMPLETED
Smoking Cessation
Sanofi
 2004-09 PHASE3
NCT00481923 COMPLETED
Obesity
Sanofi
 2004-05 PHASE3
NCT00464256 COMPLETED
Smoking Cessation
Sanofi
 2004-04 PHASE3
NCT00386061 COMPLETED
Obesity
Sanofi
 2001-10 PHASE3
NCT00029848 COMPLETED
Obesity; Diabetes Mellitus, Non-Insulin-Dependent; Obesity in Diabetes
Sanofi
 2001-10 PHASE3
NCT00029861 COMPLETED
Obesity; Weight Loss
Sanofi
 2001-08 PHASE3
NCT00029835 COMPLETED
Obesity; Dyslipidemia
Sanofi
 2001-09 PHASE3
NCT00464165 COMPLETED
Smoking Cessation
Sanofi
 2002-11 PHASE3
NCT00358228 COMPLETED
Smoking Cessation
Sanofi
 2002-09 PHASE3

(data from https://clinicaltrials.gov, updated on 2022-11-21)

Check the Rimonabant (SR141716) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Rimonabant functions as a selective antagonist of the central cannabinoid receptor 1 (CB1), directly blocking downstream endocannabinoid-mediated signaling cascades and metabolic biochemical pathways. By inhibiting these signaling cascades to alter cellular lipid metabolism and cell cycle progression, this compound produces metabolic regulatory effects directly relevant to its clinical evaluation in obesity, type 2 diabetes, and cannabis dependence.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.